Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	681.54	661.82	607.52	667.24	579.78	520.4
Revenue Growth (YoY)	4.54%	8.94%	-8.95%	15.09%	11.41%	32.50%
Cost of Revenue	75.91	77.91	83.78	87.22	75.06	52.46
Gross Profit	605.63	583.91	523.74	580.02	504.71	467.94
Selling, General & Admin	380.11	335.78	336.36	377.22	304.76	200.68
Research & Development	108.8	108.8	91.59	74.55	90.47	75.96
Amortization of Goodwill & Intangibles	83.17	77.98	82.39	82.63	29.99	15.7
Operating Expenses	572.08	522.56	510.34	534.4	425.22	292.34
Operating Income	33.55	61.36	13.4	45.61	79.5	175.6
Interest Expense	-	-	-2.42	-7.07	-23.42	-23.75
Interest & Investment Income	0	-	-	-	10.22	14.35
Other Non Operating Income (Expenses)	16.2	16.2	10.45	21.68	-	-
EBT Excluding Unusual Items	49.75	77.55	21.44	60.22	66.3	166.2
Gain (Loss) on Sale of Investments	0.01	0.01	-	0.01	0.35	4.35
Asset Writedown	-	-	-20.19	-	-	-
Other Unusual Items	-8.02	6.11	1.52	0.51	6.53	-1.9
Pretax Income	-20.73	97.87	2.77	60.74	73.18	168.65
Income Tax Expense	-1.62	24.01	1.45	0.03	19.75	41.7
Net Income	-19.12	73.87	1.32	60.71	53.42	126.95
Net Income to Common	-19.12	73.87	1.32	60.71	53.42	126.95
Net Income Growth	-	5512.84%	-97.83%	13.64%	-57.92%	12.29%
Shares Outstanding (Basic)	56	55	55	54	53	53
Shares Outstanding (Diluted)	56	56	56	62	54	54
Shares Change (YoY)	0.54%	0.81%	-10.01%	13.47%	1.24%	-0.24%
EPS (Basic)	-0.34	1.34	0.02	1.13	1.01	2.41
EPS (Diluted)	-0.34	1.32	0.02	1.04	0.98	2.36
EPS Growth	-	6500.00%	-98.08%	6.32%	-58.48%	12.38%
Free Cash Flow	70.75	171.23	110.53	116.41	125.08	134.71
Free Cash Flow Per Share	1.26	3.06	1.99	1.89	2.30	2.51
Gross Margin	88.86%	88.23%	86.21%	86.93%	87.05%	89.92%
Operating Margin	4.92%	9.27%	2.21%	6.84%	13.71%	33.74%
Profit Margin	-2.80%	11.16%	0.22%	9.10%	9.21%	24.39%
Free Cash Flow Margin	10.38%	25.87%	18.19%	17.45%	21.57%	25.89%
EBITDA	118.94	141.77	98.26	131.16	112.09	193.74
EBITDA Margin	17.45%	21.42%	16.17%	19.66%	19.33%	37.23%
D&A For EBITDA	85.39	80.41	84.86	85.54	32.6	18.14
EBIT	33.55	61.36	13.4	45.61	79.5	175.6
EBIT Margin	4.92%	9.27%	2.21%	6.84%	13.71%	33.74%
Effective Tax Rate	-	24.53%	52.47%	0.05%	26.99%	24.73%
Revenue as Reported	681.54	661.82	607.52	667.24	579.78	520.4

Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q